公开(公告)号：EP4227304A2

公开(公告)日：2023-08-16

申请号：EP23160414.1

申请日：2014-01-23

Applicant: Novartis AG

Inventor： AXFORD, Jake ,  DALES, Natalie ,  SUNG, Moo Je

IPC: C07D417/10 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10 ,  C07D487/20 ,  A61K31/433 ,  A61K31/435 ,  A61K31/437 ,  A61K31/438 ,  A61K31/454 ,  A61K31/496 ,  A61K31/506 ,  A61P21/00 ,  A61P21/04 ,  A61P43/00

Abstract: The present invention provides a compound of Formula (X) or a pharmaceutically acceptable salt thereof;

a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：EP3487505B1

公开(公告)日：2023-05-03

申请号：EP17743330.7

申请日：2017-07-25

Inventor： WISCHIK, Claude Michel ,  SCHELTER, Björn Olaf ,  WISCHIK, Damon Jude ,  STOREY, John Mervyn David

IPC: A61K31/5415 ,  A61P25/28 ,  A61P21/00 ,  A61P25/02 ,  A61P25/14 ,  A61P25/16 ,  A61P9/10 ,  A61P43/00 ,  A61P25/00 ,  A61P3/02 ,  A61P21/04

公开(公告)号：EP4112083A1

公开(公告)日：2023-01-04

申请号：EP21760603.7

申请日：2021-02-26

Applicant: Nippon Shinyaku Co., Ltd. ,  NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY

Inventor： HONDA Yu ,  MUCHIMA Kaname ,  FUKUI Takahiro ,  HASEGAWA Saki ,  TAKEDA Shin'ichi ,  AOKI Yoshitsugu

IPC: A61K48/00 ,  A61P21/04 ,  C07K14/47 ,  C12N15/113 ,  C12N15/12 ,  A61K31/7088

Abstract: The present specification provides a drug that causes highly-efficient skipping of exon 51 in the human dystrophin gene. The present specification provides an antisense oligomer having an activity to induce skipping of exon 51 in the human dystrophin gene.

公开(公告)号：EP4104861A1

公开(公告)日：2022-12-21

申请号：EP21738338.9

申请日：2021-01-06

Applicant: Sumitomo Pharma Co., Ltd.

Inventor： SAMPEI, Kazuaki ,  ISHIYAMA, Takeo ,  IKEDA, Atsushi ,  ISHIKAWA, Taizo ,  HIGUCHI, Makoto ,  TAKUWA, Hiroyuki ,  TAKADO, Yuhei

IPC: A61K45/00 ,  A61P21/02 ,  A61P21/04 ,  A61P25/16 ,  A61P25/28 ,  A61P43/00 ,  C07D237/14 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04

Abstract: The present invention is to provide a medicament for treating and/or preventing tauopathy by activating the voltage-gated sodium channel (Nav). The present invention relates to a medicament for treating and/or preventing tauopathy, comprising a Nav activator as an active ingredient.

公开(公告)号：EP3268007B1

公开(公告)日：2022-11-09

申请号：EP16764296.6

申请日：2016-03-10

Inventor： WASIAK, Sylwia ,  KULIKOWSKI, Ewelina, B. ,  HALLIDAY, Christopher, R.A. ,  GILHAM, Dean ,  TSUJIKAWA, Laura ,  HANSEN, Henrik C.

IPC: A61K31/551 ,  A61K31/517 ,  A61P37/02 ,  C07D239/91 ,  C07D403/04 ,  C07D403/10 ,  A61P3/12 ,  A61P7/02 ,  A61P7/10 ,  A61P9/14 ,  A61P13/02 ,  A61P21/02 ,  A61P21/04 ,  A61P25/00 ,  A61P27/02 ,  C07D403/12 ,  A61P13/12 ,  A61P43/00

公开(公告)号：EP3995153A1

公开(公告)日：2022-05-11

申请号：EP20833586.9

申请日：2020-06-18

Applicant: KNC Laboratories Co., Ltd. ,  Kobe Gakuin Educational Foundation

Inventor： MATSUO, Masafumi ,  MAETA, Kazuhiro

IPC: A61K48/00 ,  A61P3/10 ,  A61P7/00 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P13/12 ,  A61P19/02 ,  A61P19/08 ,  A61P21/02 ,  A61P21/04 ,  A61P29/00 ,  A61P43/00 ,  A23K20/153 ,  A23L33/13 ,  C12N15/113 ,  A61K31/7088 ,  A61K31/712 ,  A61K31/7125

Abstract: A novel method of myostatin inhibition is provided.
An antisense oligonucleotide of 15-30 bases or a salt or a solvate thereof, wherein the antisense oligonucleotide has a nucleotide sequence complementary to a target site in exon 1 of the myostatin gene and is capable of inhibiting the production of the mRNA of the myostatin gene. A pharmaceutical drug, a food, a feed, an agent for promoting myocyte proliferation and/or hypertrophy, an agent for increasing muscle mass and/or inhibiting muscle weakness, an agent for inhibiting production of the mRNA of the myostatin gene, and an inhibitor of the function of myostatin, each of which comprises the above antisense oligonucleotide or a salt or a solvate thereof.

公开(公告)号：EP3253412B1

公开(公告)日：2022-03-23

申请号：EP16747111.9

申请日：2016-02-02

Inventor： LINCECUM, John, M. ,  JIANG, Bingbing ,  PERRIN, Steven, N. ,  GILL, Alan ,  GILL, Cynthia, A. ,  VIEIRA, Fernando G.

IPC: C07K16/28 ,  A61K39/395 ,  A61P21/00 ,  A61P21/04 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28 ,  A61P29/00 ,  A61P37/02

公开(公告)号：EP3912971A1

公开(公告)日：2021-11-24

申请号：EP20748154.0

申请日：2020-01-21

Applicant: Changchun Huayuan High-Science and Technology Co., Ltd ,  Jiangsu Sheneryang High-Science and Technology Co., Ltd

Inventor： WANG, Tonghui ,  ZHANG, Ju ,  WANG, Lihua ,  WANG, Depu ,  ZHANG, Yaxin ,  YU, Qinghua ,  ZHANG, Qi ,  LI, Mingze

IPC: C07D219/10 ,  C07C51/43 ,  C07C55/10 ,  A61K31/473 ,  A61P25/28 ,  A61P25/18 ,  A61P25/00 ,  A61P21/04 ,  A61P21/00

Abstract: A cholinesterase inhibitor polymorph, wherein specifically disclosed are a octahydroaminoacridine succinate polymorph, a corresponding crystal composition and pharmaceutical composition, and applications thereof. The compound octahydroaminoacridine succinate is used for screening and studying polymorphs, and the discovered polymorphs are appraised and evaluated; crystal forms having better physical and chemical properties are determined for subsequent development and study, and crystal forms having good stability and an excellent therapeutic effect are obtained.

公开(公告)号：EP3858376A1

公开(公告)日：2021-08-04

申请号：EP20189872.3

申请日：2015-03-12

Applicant: Precision Biosciences, Inc.

Inventor： JANTZ, Derek ,  SMITH, James Jefferson ,  NICHOLSON, Michael G.

IPC: A61K38/46 ,  A61K38/54 ,  C07K14/47 ,  C12N15/00 ,  C12N9/22 ,  C12N7/00 ,  A61P21/00 ,  A61P21/04 ,  A61P43/00 ,  A61K48/00

Abstract: The invention relates to the field of molecular biology and recombinant nucleic acid technology. In particular, the invention relates to a method of treating a patient with Duchenne Muscular Dystrophy comprising the removal of at least one exon from the dystrophin gene using engineered nucleases.

公开(公告)号：EP3286301B1

公开(公告)日：2021-07-28

申请号：EP16782394.7

申请日：2016-04-22

Inventor： SCHMIDT, Uli ,  CARON, Leslie

IPC: C12N5/077 ,  A61K35/34 ,  C12N5/02 ,  A61K35/545 ,  G01N33/20 ,  A61P21/00 ,  A61P21/04